Standout Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma 2005 2026 2012 2019 6.2k
  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer (2015)
    Pasi A. Jänne, James Chih‐Hsin Yang et al. New England Journal of Medicine
  3. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer (2005)
    Toshimi Takano, Yuichiro Ohe et al. Journal of Clinical Oncology
  4. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan (2006)
    Yuichiro Ohe, Yasuo Ohashi et al. Annals of Oncology
  5. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study (2013)
    Takashi Seto, Katsuyuki Kiura et al. The Lancet Oncology
  6. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer (2017)
    Suresh S. Ramalingam, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  7. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer (2020)
    Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology
  8. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial (2022)
    Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology
  9. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (2023)
    Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications

Immediate Impact

1 by Nobel laureates 10 from Science/Nature 188 standout
Sub-graph 1 of 12

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
2023 Standout
26 intermediate papers

Works of Yuichiro Ohe being referenced

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Yuichiro Ohe 14053 14605 5783 555 21.3k
D. Ross Camidge 14715 16480 8384 533 23.6k
Lucio Crinò 13280 13143 5395 372 19.0k
Nagahiro Saijo 16116 13140 9018 551 25.0k
David Planchard 10676 9668 4533 423 15.9k
Benjamin Solomon 12283 13677 6482 407 20.0k
Benjamin Besse 11848 10121 5484 697 18.1k
Nobuyuki Yamamoto 11327 12301 3903 571 16.9k
David R. Gandara 16654 18069 7907 641 29.1k
Yuichi Ishikawa 8636 9529 7358 262 17.5k
David R. Spigel 14076 9703 4947 603 19.4k

All Works

Loading papers...

Rankless by CCL
2026